SCM
TERN

Silverarc Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Silverarc Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250,551
Closed -$1.64M – 87
2024
Q1 		$1.64M Sell
250,551
-266,448
-52% -$1.74M 0.46% 53
2023
Q4 		$3.36M Buy
516,999
+16,999
+3% +$89.9K 1% 37
2023
Q3 		$2.52M Sell
500,000
-99,668
-17% -$632K 0.76% 42
2023
Q2 		$5.25M Sell
599,668
-68,254
-10% -$796K 1.62% 21
2023
Q1 		$7.91M Sell
667,922
-32,078
-5% -$307K 3.26% 6
2022
Q4 		$7.13M Buy
700,000
+685,527
+4,737% +$4.56M 2.04% 18
2022
Q3 		$85K Buy
+14,473
New +$53.8K 0.03% 76

Other funds holding TERN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Silverarc Capital Management's TERN Position: Q2 2024 in Review

Silverarc Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2024, closing a stake of 250,551 shares — an estimated $1.64M sold.

Silverarc Capital Management first reported a position in TERN in Q3 2022 and held it in 7 quarters. The position peaked at $7.91M in Q1 2023. 126 funds tracked by Wall St. Rank hold TERN as of Q2 2024.

  • Silverarc Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 250,551 Terns Pharmaceuticals shares in Q2 2024, an estimated $1.64M.
  • Silverarc Capital Management first reported a position in Terns Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Silverarc Capital Management's Terns Pharmaceuticals position peaked at $7.91M in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2024.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.